2nd Bioengineering & Translational Medicine Conference

October 28-29, 2017

Following the success of last year's conference, the 2nd Bioengineering & Translational Medicine Conference will bring together top researchers from academia and industry to discuss advances in the development, clinical and commercial translation of biological technologies and will provide opportunities for exchanging ideas and networking with leaders in the field. 

Generously Supported by the National Science Foundation

From Left, Samir Mitragotri, Efie Kokkoli, Kannan Rangaramunujam, Mark Prausnitz

From Left, Samir Mitragotri, Efie Kokkoli, Kannan Rangaramunujam, Mark Prausnitz 

The conference will feature cutting edge advances in biopharmaceuticals, gene and drug delivery, immunoengineering, biomanufacturing, stem cells, regenerative medicine and their translation in a single-track conference format.

Conference Chairs:

  • Ali Khademhosseini, Harvard University 
  • Efie Kokkoli, University of Minnesota

Organizing Committee:

  • Kim Chaffin, Medtronic
  • Ashish Garg, Eli Lilly and Company
  • Justin Hanes, Johns Hopkins University
  • Ravi Kane, Georgia Institute of Technology
  • Richard Korsmeyer, Pfizer
  • Antonios Mikos, Rice University
  • Samir Mitragotri, University of California, Santa Barbara
  • Ian Parney, Mayo Clinic
  • Nicholas Peppas, The University of Texas at Austin
  • Mark Prausnitz, Georgia Institute of Technology


  • Biopharmaceuticals
  • Gene and Drug Delivery
  • Immunoengineering
  • Biomanufacturing
  • Stem Cells/ Regenerative Medicine
  • Translation (VC, IP, regulatory, business)

Invited Speakers:

  • Juergen Hahn, Rensselaer Polytechnic Institute    
  • Rangamanujam Kannan, Johns Hopkins University    
  • Michael Look, Pfizer    
  • Michael McAlpine, University of Minnesota
  • Stelios Andreadis, University at Buffalo, SUNY  


  • Arindam Bose, AbiologicsB, LLC
  • Paul Burke, Burke Bioventures
  • Scott McIvor, University of Minnesota, Discovery Genomics Inc., Immunosoft Corp.    
  • John Santini, Vergent Bioscience  
  • Nicholas Peppas, The University of Texas at Austin
  • Bill Kaemmerer, CGTA Research Group

Featured Speakers

Stelios T. Andreadis

Stelios T. Andreadis received his M.S. (Applied Mathematics) and Ph.D. degree in Chemical Engineering from the University of Michigan studying the dynamics of retroviral gene transfer for gene therapy. He then pursued postdoctoral training at the Center for Engineering in Medicine at Harvard Medical School, where he worked in the areas of gene therapy, tissue engineering and regenerative medicine. Currently he serves as Professor and Chair of Chemical and Biological Engineering, Professor of Biomedical Engineering and Member of the Center of Excellence in Bioinformatics and Life Sciences...Read more

Arindam Bose

Arindam Bose is currently an Independent Consultant in biologics process development and manufacturing following a 35-year career in bioprocess development, clinical supply manufacturing, external partnering, corporate biotechnology strategy and advocacy for science-based regulations for biologics at Pfizer Worldwide R&D. He served as the Technical Lead of the Team that developed and executed Pfizer’s strategy for entry into the field of biosimilar medicines. Dr. Bose is a Member of the US National Academy of Engineering. Additionally, he was elected Fellow of AIChE, American...Read more

Paul Burke

Paul Burke is Principal of Burke Bioventures LLC, a biotechnology consultancy providing strategic advice and scientific direction for biotechnology, pharmaceutical, and drug delivery companies, with a particular focus on nanotechnology, targeting, and RNA.  Dr. Burke brings two decades of biopharmaceutical industry experience, having served in executive roles at Amgen, Merck, and Pfizer where he specialized in launching and directing new technology initiatives for transforming discovery and preclinical pipelines.  He received his PhD in Biological Chemistry from the Massachusetts...Read more

Juergen Hahn

Juergen Hahn is the department head of the Department of Biomedical Engineering at Rensselaer Polytechnic Institute in addition to holding an appointment in the Department of Chemical & Biological Engineering. He received his Diploma degree in engineering from RWTH Aachen, Germany, in 1997, and his MS and Ph.D. degrees in chemical engineering from the University of Texas, Austin, in 1998 and 2002, respectively. He was a post-doctoral researcher at the Chair for Process Systems Engineering at RWTH Aachen, Germany, before joining the Department of Chemical Engineering at Texas A&M...Read more

Bill Kaemmerer

Neuroscientist with extensive experience in the delivery of AAV to the brain. Available for consulting or contractual assignments. I am particularly passionate about advancing and facilitating the development of DNA-based therapies for Huntington’s disease and other neurological disorders into Phase I clinical trials. For this reason, I co-founded the not-for-profit CGTA Research Group.

My experience includes developing strategic programs of research and serving as a leader of a team of Ph.D. and Master's level scientists using molecular biology, in vitro cell culture,...Read more

Michael C. McAlpine

Michael C. McAlpine is the Benjamin Mayhugh Associate Professor of Mechanical Engineering at the University of Minnesota. Previously, he was an Assistant Professor of Mechanical and Aerospace Engineering at Princeton University (2008-2015). He received a B.S. in Chemistry with honors from Brown University (2000) and a Ph.D. in Chemistry from Harvard University (2006). His research is focused on 3D printing functional materials & devices, including the three-dimensional interweaving of biological and electronic materials using 3D printing. He has received a number of awards, including...Read more

Nicholas Peppas

Nicholas A. Peppas is the Cockrell Family Regents Chaired Professor in the Cockrell College of Engineering (Chemical, Biomedical Engineering), Dell Medical School (Pediatrics, Surgery and Postoperative Care) and the College of Pharmacy at UT Austin. 

He has worked in biomaterials, drug/protein delivery, tissue engineering and bionanotechnology blending modern molecular and cellular biology with engineering and materials. 

About 50 US patents issued or pending. Most technology has been assigned to major pharmaceuticcal and medical companies...Read more

Kannan Rangaramanujam

Dr. Kannan Rangaramanujam is the Arnall Patz distinguished professor of ophthalmology and co-director of center for nanomedicine at the Wilmer Eye Institute at Johns Hopkins School of Medicine. He has joint/courtesy appointments in Chemical and Biomolecular Engineering, and Materials Science and Engineering at Johns Hopkins. He is also a research scientist at the Kennedy-Krieger Institute. He obtained his PhD in Chemical Engineering from the California Institute of Technology, and followed it with a post-doc from the University of Minnesota. His research interested are in...Read more

John Santini

Dr. Santini is a startup company executive, serial entrepreneur, inventor, and scientist that has spent his career focused on the creation and growth of businesses developing next-generation pharmaceuticals, drug delivery systems, biosensors, and mobile health products. Prior his current roles as CEO of Vergent Bioscience and Board Member/co-founder of Univ. of Minnesota biotech spinout ApoGen Biotechnologies, he served as the CEO or CTO of four healthcare startups – MicroCHIPS, On Demand Therapeutics, RadioRx, and IRISense – developing products such as novel cancer...Read more


Proceedings of the 2nd Bioengineering & Translational Medicine Conference are now available: